Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

126 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of efficacy of romosozumab with denosumab and risedronate in patients newly initiating glucocorticoid therapy.
Kawazoe M, Kaneko K, Masuoka S, Yamada S, Yamada Z, Muraoka S, Furukawa K, Sato H, Watanabe E, Koshiba K, Irita I, Kanaji M, Sugihara T, Nishio J, Nanki T. Kawazoe M, et al. J Clin Endocrinol Metab. 2024 Nov 18:dgae810. doi: 10.1210/clinem/dgae810. Online ahead of print. J Clin Endocrinol Metab. 2024. PMID: 39552045
OBJECTIVE: To compare the efficacy of romosozumab (ROMO), a monoclonal antibody against sclerostin, with existing therapy for GIOP. METHODS: Patients with rheumatic diseases who had not previously received treatment for osteoporosis and were newly treated with predn …
OBJECTIVE: To compare the efficacy of romosozumab (ROMO), a monoclonal antibody against sclerostin, with existing therapy for …
Complete versus incomplete revascularization in patients with a non-ST-elevation myocardial infarction: Analysis from the e-ULTIMASTER registry.
Jiménez Díaz VA, Routledge H, Malik FT, Hildick-Smith D, Guédès A, Baello P, Kuramitsu S, Das R, Dewilde W, Portales JF, Angioi M, Smits PC, Romo AI. Jiménez Díaz VA, et al. Cardiovasc Revasc Med. 2024 Jul 22:S1553-8389(24)00588-8. doi: 10.1016/j.carrev.2024.07.011. Online ahead of print. Cardiovasc Revasc Med. 2024. PMID: 39079857 Free article.
An HPLC-UV Method to Assess Human Plasma 25(OH)D3.
Tijerina A, Garza A, López A, Cavazos N, Romo A, Heya MS, Bouzas C, Tur JA, Salas R. Tijerina A, et al. Nutrients. 2024 Jul 18;16(14):2304. doi: 10.3390/nu16142304. Nutrients. 2024. PMID: 39064747 Free PMC article.
A multicentric outbreak of Candida auris in Mexico: 2020 to 2023.
la Garza PR, Cruz-de la Cruz C, Bejarano JIC, Romo AEL, Delgado JV, Ramos BA, Neira MNM, Rodríguez DS, Rodríguez HMS, Selvera OAR. la Garza PR, et al. Am J Infect Control. 2024 Dec;52(12):1384-1389. doi: 10.1016/j.ajic.2024.07.012. Epub 2024 Jul 24. Am J Infect Control. 2024. PMID: 39059713
Romosozumab versus parathyroid hormone receptor agonists: which osteoanabolic to choose and when?
Anastasilakis AD, Yavropoulou MP, Palermo A, Makras P, Paccou J, Tabacco G, Naciu AM, Tsourdi E. Anastasilakis AD, et al. Eur J Endocrinol. 2024 Jul 2;191(1):R9-R21. doi: 10.1093/ejendo/lvae076. Eur J Endocrinol. 2024. PMID: 38938063 Review.
The PTH receptor 1 (PTH1R) agonists teriparatide (TPTD) and abaloparatide (ABL) increase bone formation, bone mineral density (BMD), and bone strength by activating PTH receptors on osteoblasts. Romosozumab (ROMO), a humanized monoclonal antibody against sclerostin, …
The PTH receptor 1 (PTH1R) agonists teriparatide (TPTD) and abaloparatide (ABL) increase bone formation, bone mineral density (BMD), and bon …
126 results